ESTRADIOL TABLETS, USP

estradiol (Estradioltablet 
[Mylan Pharmaceuticals Inc.]

0.5 mg, 1 mg and 2 mg

Rx only

WARNINGS

ESTROGENS HAVE BEEN REPORTED TO INCREASE THE RISK OF ENDOMETRIAL CARCINOMA IN POSTMENOPAUSAL WOMEN

Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that "natural" estrogens are more or less hazardous than "synthetic" estrogens at equiestrogenic doses.

ESTROGENS SHOULD NOT BE USED DURING PREGNANCY

There is no indication for estrogen therapy during pregnancy or during the immediate postpartum period. Estrogens are ineffective for the prevention or treatment of threatened or habitual abortion. Estrogens are not indicated for the prevention of postpartum breast engorgement.

Estrogen therapy during pregnancy is associated with an increased risk of congenital defects in the reproductive organs of the fetus, and possibly other birth defects. Studies of women who received diethylstilbestrol (DES) during pregnancy have shown that female offspring have an increased risk of vaginal adenosis, squamous cell dysplasia of the uterine cervix, and clear cell vaginal cancer later in life; male offspring have an increased risk of urogenital abnormalities and possibly testicular cancer later in life. The 1985 DES Task Force concluded that use of DES during pregnancy is associated with a subsequent increased risk of breast cancer in the mothers, although a causal relationship remains unproven and the observed level of excess risk is similar to that for a number of other breast cancer risk factors.

DESCRIPTION

Each tablet, for oral administration, contains 0.5, 1 or 2 mg of micronized estradiol. Estradiol (17β-estradiol) is a white, crystalline solid, chemically described as estra-1,3,5(10)-triene-3,17β-diol. Estradiolís structural formula, molecular formula, and molecular weight are as follows:

Image from Drug Label Content

In addition, each tablet contains the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate. The 1 mg tablet also contains FD&C Red #40 lake and the 2 mg tablet also contains FD&C Blue #1 lake.

CLINICAL PHARMACOLOGY

Estrogen drug products act by regulating the transcription of a limited number of genes. Estrogens diffuse through cell membranes, distribute themselves throughout the cell, and bind to and activate the nuclear estrogen receptor, a DNA-binding protein which is found in estrogen-responsive tissues. The activated estrogen receptor binds to specific DNA sequences, or hormone-response elements, which enhance the transcription of adjacent genes and in turn lead to the observed effects. Estrogen receptors have been identified in tissues of the reproductive tract, breast, pituitary, hypothalamus, liver, and bone of women.

Estrogens are important in the development and maintenance of the female reproductive system and secondary sex characteristics. By a direct action, they cause growth and development of the uterus, fallopian tubes, and vagina. With other hormones, such as pituitary hormones and progesterone, they cause enlargement of the breasts through promotion of ductal growth, stromal development, and the accretion of fat. Estrogens are intricately involved with other hormones, especially progesterone, in the processes of the ovulatory menstrual cycle and pregnancy, and affect the release of pituitary gonadotropins. They also contribute to the shaping of the skeleton, maintenance of tone and elasticity of urogenital structures, changes in the epiphyses of the long bones that allow for the pubertal growth spurt and its termination, and pigmentation of the nipples and genitals.

Estrogens occur naturally in several forms. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. This is converted primarily to estrone, which circulates in roughly equal proportion to estradiol, and to small amounts of estriol. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone – especially in its sulfate ester form – is the most abundant circulating estrogen in postmenopausal women. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than estrone or estriol at the receptor.

Estrogens used in therapy are well absorbed through the skin, mucous membranes, and gastrointestinal tract. When applied for a local action, absorption is usually sufficient to cause systemic effects. When conjugated with aryl and alkyl groups for parenteral administration, the rate of absorption of oily preparations is slowed with a prolonged duration of action, such that a single intramuscular injection of estradiol valerate or estradiol cypionate is absorbed over several weeks.

Administered estrogens and their esters are handled within the body essentially the same as the endogenous hormones. Metabolic conversion of estrogens occurs primarily in the liver (first pass effect), but also at local target tissue sites. Complex metabolic processes result in a dynamic equilibrium of circulating conjugated and unconjugated estrogenic forms which are continually interconverted, especially between estrone and estradiol and between esterified and unesterified forms. Although naturally-occurring estrogens circulate in the blood largely bound to sex hormone-binding globulin and albumin, only unbound estrogens enter target tissue cells. A significant proportion of the circulating estrogen exists as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogenic species. A certain proportion of the estrogen is excreted into the bile and then reabsorbed from the intestine. During this enterohepatic recirculation, estrogens are desulfated and resulfated and undergo degradation through conversion to less active estrogens (estriol and other estrogens), oxidation to nonestrogenic substances (catecholestrogens, which interact with catecholamine metabolism, especially in the central nervous system), and conjugation with glucuronic acids (which are then rapidly excreted in the urine).

When given orally, naturally-occurring estrogens and their esters are extensively metabolized (first pass effect) and circulate primarily as estrone sulfate, with smaller amounts of other conjugated and unconjugated estrogenic species. This results in limited oral potency. By contrast, synthetic estrogens, such as ethinyl estradiol and the nonsteroidal estrogens, are degraded very slowly in the liver and other tissues, which results in their high intrinsic potency. Estrogen drug products administered by non-oral routes are not subject to first-pass metabolism, but also undergo significant hepatic uptake, metabolism, and enterohepatic recycling.

INDICATIONS AND USAGE

Estradiol Tablets, USP are indicated in the:

1.
Treatment of moderate to severe vasomotor symptoms associated with the menopause. There is no adequate evidence that estrogens are effective for nervous symptoms or depression which might occur during menopause and they should not be used to treat these conditions.
2.
Treatment of vulval and vaginal atrophy.
3.
Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure.
4.
Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease.
5.
Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).
6.
Prevention of osteoporosis.

Since estrogen administration is associated with risk, selection of patients should ideally be based on prospective identification of risk factors for developing osteoporosis. Unfortunately, there is no certain way to identify those women who will develop osteoporotic fractures. Most prospective studies of efficacy for this indication have been carried out in white menopausal women, without stratification by other risk factors, and tend to show a universally salutary effect on bone. Thus, patient selection must be individualized based on the balance of risks and benefits. A more favorable risk/benefit ratio exists in a hysterectomized woman because she has no risk of endometrial cancer (see BOXED WARNINGS).

Estrogen replacement therapy reduces bone resorption and retards or halts postmenopausal bone loss. Case-control studies have shown an approximately 60 percent reduction in hip and wrist fractures in women whose estrogen replacement was begun within a few years of menopause. Studies also suggest that estrogen reduces the rate of vertebral fractures. Even when started as late as 6 years after menopause, estrogen prevents further loss of bone mass for as long as the treatment is continued. The results of a two-year, randomized, placebo-controlled, double-blind, dose-ranging study have shown that treatment with 0.5 mg estradiol daily for 23 days (of a 28 day cycle) prevents vertebral bone mass loss in postmenopausal women. When estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period. There is no evidence that estrogen replacement therapy restores bone mass to premenopausal levels.

At skeletal maturity there are sex and race differences in both the total amount of bone present and its density, in favor of men and blacks. Thus, women are at higher risk than men because they start with less bone mass and, for several years following natural or induced menopause, the rate of bone mass decline is accelerated. White and Asian women are at higher risk than black women.

Early menopause is one of the strongest predictors for the development of osteoporosis. In addition, other factors affecting the skeleton which are associated with osteoporosis include genetic factors (small build, family history), and endocrine factors (nulliparity, thyrotoxicosis, hyperparathyroidism, Cushing's syndrome, hyperprolactinemia, Type I diabetes), lifestyle (cigarette smoking, alcohol abuse, sedentary exercise habits) and nutrition (below average body weight, dietary calcium intake).

The mainstays of prevention and management of osteoporosis are estrogen, an adequate lifetime calcium intake, and exercise. Postmenopausal women absorb dietary calcium less efficiently than premenopausal women and require an average of 1500 mg/day of elemental calcium to remain in neutral calcium balance. By comparison, premenopausal women require about 1000 mg/day and the average calcium intake in the USA is 400 to 600 mg/day. Therefore, when not contraindicated, calcium supplementation may be helpful.

Weight-bearing exercise and nutrition may be important adjuncts to the prevention and management of osteoporosis. Immobilization and prolonged bed rest produce rapid bone loss, while weight-bearing exercise has been shown both to reduce bone loss and to increase bone mass. The optimal type and amount of physical activity that would prevent osteoporosis have not been established, however in two studies an hour of walking and running exercise twice or three times weekly significantly increased lumbar spine bone mass.

CONTRAINDICATIONS

Estrogens should not be used in individuals with any of the following conditions:

1.
Known or suspected pregnancy (see BOXED WARNINGS). Estrogens may cause fetal harm when administered to a pregnant woman.
2.
Undiagnosed abnormal genital bleeding.
3.
Known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease.
4.
Known or suspected estrogen-dependent neoplasia.
5.
Active thrombophlebitis or thromboembolic disorders.

WARNINGS

Induction of Malignant Neoplasms

Endometrial Cancer

The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 fold greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than one year. The greatest risk appears associated with prolonged use – with increased risks of 15 to 24 fold for five to ten years or more. In three studies, persistence of risk was demonstrated for 8 to over 15 years after cessation of estrogen treatment. In one study a significant decrease in the incidence of endometrial cancer occurred six months after estrogen withdrawal. Concurrent progestin therapy may offset this risk but the overall health impact in postmenopausal women is not known (see PRECAUTIONS).

Breast Cancer

While the majority of studies have not shown an increased risk of breast cancer in women who have ever used estrogen replacement therapy, some have reported a moderately increased risk (relative risks of 1.3 to 2) in those taking higher doses or those taking lower doses for prolonged periods of time, especially in excess of 10 years. Other studies have not shown this relationship.

Congenital Lesions with Malignant Potential

Estrogen therapy during pregnancy is associated with an increased risk of fetal congenital reproductive tract disorders, and possibly other birth defects. Studies of women who received DES during pregnancy have shown that female offspring have an increased risk of vaginal adenosis, squamous cell dysplasia of the uterine cervix, and clear cell vaginal cancer later in life; male offspring have an increased risk of urogenital abnormalities and possibly testicular cancer later in life. Although some of these changes are benign, others are precursors of malignancy.

Gallbladder Disease

Two studies have reported a 2 to 4 fold increase in the risk of gallbladder disease requiring surgery in women receiving postmenopausal estrogens.

Cardiovascular Disease

Large doses of estrogen (5 mg conjugated estrogens per day), comparable to those used to treat cancer of the prostate and breast, have been shown in a large prospective clinical trial in men to increase the risks of nonfatal myocardial infarction, pulmonary embolism, and thrombophlebitis. These risks cannot necessarily be extrapolated from men to women. However, to avoid the theoretical cardiovascular risk to women caused by high estrogen doses, the dose for estrogen replacement therapy should not exceed the lowest effective dose.

Elevated Blood Pressure

Occasional blood pressure increases during estrogen replacement therapy have been attributed to idiosyncratic reactions to estrogens. More often, blood pressure has remained the same or has dropped. One study showed that postmenopausal estrogen users have higher blood pressure than nonusers. Two other studies showed slightly lower blood pressure among estrogen users compared to nonusers. Postmenopausal estrogen use does not increase the risk of stroke. Nonetheless, blood pressure should be monitored at regular intervals with estrogen use.

Hypercalcemia

Administration of estrogens may lead to severe hypercalcemia in patients with breast cancer and bone metastases. If this occurs, the drug should be stopped and appropriate measures taken to reduce the serum calcium level.

PRECAUTIONS

General

Addition of a Progestin

Studies of the addition of a progestin for seven or more days of a cycle of estrogen administration have reported a lowered incidence of endometrial hyperplasia which would otherwise be induced by estrogen treatment. Morphological and biochemical studies of endometrium suggest that 10 to 14 days of progestin are needed to provide maximal maturation of the endometrium and to eliminate any hyperplastic changes. There are possible additional risks which may be associated with the inclusion of progestins in estrogen replacement regimens. These include: (1) adverse effects on lipoprotein metabolism (lowering HDL and raising LDL) which may diminish the possible cardioprotective effect of estrogen therapy (see PRECAUTIONS: Drug/Laboratory Test Interactions); (2) impairment of glucose tolerance; and (3) possible enhancement of mitotic activity in breast epithelial tissue (although few epidemiological data are available to address this point). The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues remain to be clarified.

Physical Examination

A complete medical and family history should be taken prior to the initiation of any estrogen therapy. The pretreatment and periodic physical examinations should include special reference to blood pressure, breasts, abdomen, and pelvic organs, and should include a Papanicolaou smear. As a general rule, estrogen should not be prescribed for longer than one year without reexamining the patient.

Hypercoagulability

Some studies have shown that women taking estrogen replacement therapy have hypercoagulability, primarily related to decreased antithrombin activity. This effect appears dose- and duration-dependent and is less pronounced than that associated with oral contraceptive use. Also, postmenopausal women tend to have increased coagulation parameters at baseline compared to premenopausal women. There is some suggestion that low dose postmenopausal mestranol may increase the risk of thromboembolism, although the majority of studies (of primarily conjugated estrogens users) report no such increase. There is insufficient information on hypercoagulability in women who have had previous thromboembolic disease.

Familial Hyperlipoproteinemia

Estrogen therapy may be associated with massive elevations of plasma triglycerides leading to pancreatitis and other complications in patients with familial defects of lipoprotein metabolism.

Fluid Retention

Because estrogens may cause some degree of fluid retention, conditions which might be exacerbated by this factor, such as asthma, epilepsy, migraine, and cardiac or renal dysfunction, require careful observation.

Uterine Bleeding and Mastodynia

Certain patients may develop undesirable manifestations of estrogenic stimulation, such as abnormal uterine bleeding and mastodynia.

Impaired Liver Function

Estrogens may be poorly metabolized in patients with impaired liver function and should be administered with caution.

Information for the Patient

See text of Patient Leaflet below.

Laboratory Tests

Estrogen administration should generally be guided by clinical response at the smallest dose, rather than laboratory monitoring, for relief of symptoms for those indications in which symptoms are observable. For prevention of osteoporosis, however, see DOSAGE AND ADMINISTRATION.

Drug/Laboratory test Interactions

1.
Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.
2.
Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay. T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered.
3.
Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased circulating corticosteroids and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).
4.
Increased plasma HDL and HDL-2 subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels.
5.
Impaired glucose tolerance.
6.
Reduced response to metyrapone test.
7.
Reduced serum folate concentration.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

Long term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver. See CONTRAINDICATIONS and WARNINGS.

Pregnancy

Teratogenic Effect. Pregnancy Category X

Estrogens should not be used during pregnancy. See CONTRAINDICATIONS and BOXED WARNINGS.

Nursing Mothers

As a general principle, the administration of any drug to nursing mothers should be done only when clearly necessary since many drugs are excreted in human milk. In addition, estrogen administration to nursing mothers has been shown to decrease the quantity and quality of the milk.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established. Large and repeated doses of estrogen over an extended period of time have been shown to accelerate epiphyseal closure, resulting in short adult stature if treatment is initiated before the completion of physiologic puberty in normally developing children. In patients in whom bone growth is not complete, periodic monitoring of bone maturation and effects on epiphyseal centers is recommended.

Estrogen treatment of prepubertal children also induces premature breast development and vaginal cornification, and may potentially induce vaginal bleeding in girls. In boys, estrogen treatment may modify the normal pubertal process. All other physiological and adverse reactions shown to be associated with estrogen treatment of adults could potentially occur in the pediatric population, including thromboembolic disorders and growth stimulation of certain tumors. Therefore, estrogens should only be administered to pediatric patients when clearly indicated and the lowest effective dose should always be utilized.

ADVERSE REACTIONS

The following additional adverse reactions have been reported with estrogen therapy (see WARNINGS regarding induction of neoplasia, adverse effects on the fetus, increased incidence of gallbladder disease, cardiovascular disease, elevated blood pressure, and hypercalcemia).

Genitourinary System:

 
Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding, spotting.
 
Increase in size of uterine leiomyomata.
 
Vaginal candidiasis.
 
Change in amount of cervical secretion.

Breasts:

 
Tenderness, enlargement.

Gastrointestinal:

 
Nausea, vomiting.
 
Abdominal cramps, bloating.
 
Cholestatic jaundice.
 
Increased incidence of gallbladder disease.

Skin:

 
Chloasma or melasma which may persist when drug is discontinued.
 
Erythema multiforme.
 
Erythema nodosum.
 
Hemorrhagic eruption.
 
Loss of scalp hair.
 
Hirsutism.

Eyes:

 
Steepening of corneal curvature.
 
Intolerance to contact lenses.

Central Nervous System:

 
Headache, migraine, dizziness.
 
Mental depression.
 
Chorea.

Miscellaneous:

 
Increase or decrease in weight.
 
Reduced carbohydrate tolerance.
 
Aggravation of porphyria.
 
Edema.
 
Changes in libido.

OVERDOSAGE

Serious ill effects have not been reported following acute ingestion of large doses of estrogen-containing oral contraceptives by young children. Overdosage of estrogen may cause nausea and vomiting, and withdrawal bleeding may occur in females.

DOSAGE AND ADMINISTRATION

1.
For treatment of moderate to severe vasomotor symptoms, vulval and vaginal atrophy associated with the menopause, the lowest dose and regimen that will control symptoms should be chosen and medication should be discontinued as promptly as possible: Attempts to discontinue or taper medication should be made at 3-month to 6-month intervals.

The usual initial dosage range is 1 to 2 mg daily of estradiol adjusted as necessary to control presenting symptoms. The minimal effective dose for maintenance therapy should be determined by titration. Administration should be cyclic (e.g., 3 weeks on and 1 week off).

2.
For treatment of female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure: Treatment is usually initiated with a dose of 1 to 2 mg daily of estradiol, adjusted as necessary to control presenting symptoms; the minimal effective dose for maintenance therapy should be determined by titration.
3.
For treatment of breast cancer, for palliation only, in appropriately selected women and men with metastatic disease: Suggested dosage is 10 mg three times daily for a period of at least three months.
4.
For treatment of advanced androgen-dependent carcinoma of the prostate, for palliation only: Suggested dosage is 1 to 2 mg three times daily. The effectiveness of therapy can be judged by phosphatase determinations as well as by symptomatic improvement of the patient.
5.
For prevention of osteoporosis: Therapy with Estradiol Tablets, USP to prevent postmenopausal bone loss should be initiated as soon as possible after menopause. A daily dosage of 0.5 mg should be administered cyclically (i.e., 23 days on and 5 days off). The dosage may be adjusted if necessary to control concurrent menopausal symptoms. Discontinuation of estrogen replacement therapy may re-establish the natural rate of bone loss.

HOW SUPPLIED

Estradiol Tablets, USP are available containing 0.5 mg, 1 mg and 2 mg of estradiol.

The 0.5 mg tablets are white to off-white, round, flat-faced, beveled edge tablets debossed with E to the left of the score and 3 to the right of the score on one side of the tablet and M on the other side. They are available as follows:

NDC 0378-1452-01
bottles of 100 tablets

NDC 0378-1452-05
bottles of 500 tablets

The 1 mg tablets are pink, round, flat-faced, beveled edge tablets debossed with E to the left of the score and 4 to the right of the score on one side of the tablet and M on the other side. They are available as follows:

NDC 0378-1454-01
bottles of 100 tablets

NDC 0378-1454-05
bottles of 500 tablets

The 2 mg tablets are pale blue, round, flat-faced, beveled edge tablets debossed with E to the left of the score and 5 to the right of the score on one side of the tablet and M on the other side. They are available as follows:

NDC 0378-1458-01
bottles of 100 tablets

NDC 0378-1458-05
bottles of 500 tablets

STORE AT ROOM TEMPERATURE 15° TO 30°C (59° TO 86° F).

Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

Mylan Pharmaceuticals Inc.
Morgantown, WV 26505

REV MARCH 1999
ESTRT:R2

INFORMATION FOR THE PATIENT
ESTRADIOL TABLETS, USP
0.5 mg, 1 mg and 2 mg

INTRODUCTION: This leaflet describes when and how to use estrogens, and the risks and benefits of estrogen treatment.

Estrogens have important benefits but also some risks. You must decide, with your doctor, whether the risks to you of estrogen use are acceptable because of their benefits. If you use estrogens, check with your doctor to be sure you are using the lowest possible dose that works, and that you don’t use them longer than necessary. How long you need to use estrogens will depend on the reason for use.

WARNINGS

ESTROGENS INCREASE THE RISK OF CANCER OF THE UTERUS IN WOMEN WHO HAVE HAD THEIR MENOPAUSE ("CHANGE OF LIFE"): If you use any estrogen-containing drug, it is important to visit your doctor regularly and report any unusual vaginal bleeding right away. Vaginal bleeding after menopause may be a warning sign of uterine cancer. Your doctor should evaluate any unusual vaginal bleeding to find out the cause.

ESTROGENS SHOULD NOT BE USED DURING PREGNANCY: Estrogens do not prevent miscarriage (spontaneous abortion) and are not needed in the days following childbirth. If you take estrogens during pregnancy, your unborn child has a greater than usual chance of having birth defects. The risk of developing these defects is small, but clearly larger than the risk in children whose mothers did not take estrogens during pregnancy. These birth defects may affect the baby's urinary system and sex organs. Daughters born to mothers who took DES (an estrogen drug) have a higher than usual chance of developing cancer of the vagina or cervix when they become teenagers or young adults. Sons may have a higher than usual chance of developing cancer of the testicles when they become teenagers or young adults.

USES OF ESTROGEN: (Not every estrogen drug is approved for every use listed in this section. If you want to know which of these possible uses are approved for the medicine prescribed for you, ask your doctor or pharmacist to show you the professional labeling. You can also look up the specific estrogen product in a book called the "Physicians' Desk Reference", which is available in many book stores and public libraries. Generic drugs carry virtually the same labeling information as their brand name versions.)

WHO SHOULD NOT USE ESTROGENS: Estrogens should not be used:

DANGERS OF ESTROGENS:

SIDE EFFECTS: In addition to the risks listed above, the following side effects have been reported with estrogen use:

 
Nausea and vomiting.
 
Breast tenderness or enlargement.
 
Enlargement of benign tumors ("fibroids") of the uterus.
 
Retention of excess fluid. This may make some conditions worsen, such as asthma, epilepsy, migraine, heart disease, or kidney disease.
 
A spotty darkening of the skin, particularly on the face.

REDUCING RISK OF ESTROGEN USE: If you use estrogens, you can reduce your risks by doing these things:

OTHER INFORMATION: Some doctors may choose to prescribe a progestin, a different hormonal drug, for you to take together with your estrogen treatment. Progestins lower your risk of developing endometrial hyperplasia (a possible pre-cancerous condition of the uterus) while using estrogens. Taking estrogens and progestins together may also protect you from the higher risk of uterine cancer, but this has not been clearly established. Combined use of progestin and estrogen treatment may have additional risks, however. The possible risks include unhealthy effects on blood fats (especially a lowering of HDL cholesterol, the "good" blood fat which protects against heart disease risk), unhealthy effects on blood sugar (which might worsen a diabetic condition), and a possible further increase in the breast cancer risk which may be associated with long-term estrogen use. The type of progestin drug used and its dosage schedule may be important in minimizing these effects.

Your doctor has prescribed this drug for you and you alone. Do not give the drug to anyone else.

If you will be taking calcium supplements as part of the treatment to help prevent osteoporosis, check with your doctor about how much to take.

Keep this and all drugs out of the reach of children. In case of overdose, call your doctor, hospital or poison control center immediately. This leaflet provides a summary of the most important information about estrogens. If you want more information, ask your doctor or pharmacist to show you the professional labeling. The professional labeling is also published in a book called the "Physicians' Desk Reference", which is available in book stores and public libraries. Generic drugs carry virtually the same labeling information as their brand name versions.

Mylan Pharmaceuticals Inc.
Morgantown, WV 26505

REV FEBRUARY 1999
PL:ESTRT:R1


Estradiol (Estradiol)
PRODUCT INFO
Product Code0378-1452Dosage FormTABLET
Route Of AdministrationORALDEA Schedule
INGREDIENTS
Name (Active Moiety)TypeStrength
Estradiol (Estradiol) Active0.5 MILLIGRAM  In 1 TABLET
anhydrous lactoseInactive 
colloidal silicon dioxideInactive 
crospovidoneInactive 
magnesium stearateInactive 
microcrystalline celluloseInactive 
sodium lauryl sulfateInactive 
IMPRINT INFORMATION
CharacteristicAppearanceCharacteristicAppearance
ColorWHITE (white to off-white) Score2
ShapeROUNDSymbolfalse
Imprint Code E;3;M Coatingfalse
Size6mm
PACKAGING
#NDCPackage DescriptionMultilevel Packaging
10378-1452-01100 TABLET In 1 BOTTLE, PLASTICNone
20378-1452-05500 TABLET In 1 BOTTLE, PLASTICNone

Estradiol (Estradiol)
PRODUCT INFO
Product Code0378-1454Dosage FormTABLET
Route Of AdministrationORALDEA Schedule
INGREDIENTS
Name (Active Moiety)TypeStrength
Estradiol (Estradiol) Active1 MILLIGRAM  In 1 TABLET
anhydrous lactoseInactive 
colloidal silicon dioxideInactive 
crospovidoneInactive 
magnesium stearateInactive 
microcrystalline celluloseInactive 
sodium lauryl sulfateInactive 
FD&C Red #40 lakeInactive 
IMPRINT INFORMATION
CharacteristicAppearanceCharacteristicAppearance
ColorPINKScore2
ShapeROUNDSymbolfalse
Imprint Code E;4;M Coatingfalse
Size6mm
PACKAGING
#NDCPackage DescriptionMultilevel Packaging
10378-1454-01100 TABLET In 1 BOTTLE, PLASTICNone
20378-1454-05500 TABLET In 1 BOTTLE, PLASTICNone

Estradiol (Estradiol)
PRODUCT INFO
Product Code0378-1458Dosage FormTABLET
Route Of AdministrationORALDEA Schedule
INGREDIENTS
Name (Active Moiety)TypeStrength
Estradiol (Estradiol) Active2 MILLIGRAM  In 1 TABLET
anhydrous lactoseInactive 
colloidal silicon dioxideInactive 
crospovidoneInactive 
magnesium stearateInactive 
microcrystalline celluloseInactive 
sodium lauryl sulfateInactive 
FD&C Blue #1 lakeInactive 
IMPRINT INFORMATION
CharacteristicAppearanceCharacteristicAppearance
ColorBLUE (pale blue) Score2
ShapeROUNDSymbolfalse
Imprint Code E;5;M Coatingfalse
Size6mm
PACKAGING
#NDCPackage DescriptionMultilevel Packaging
10378-1458-01100 TABLET In 1 BOTTLE, PLASTICNone
20378-1458-05500 TABLET In 1 BOTTLE, PLASTICNone

Revised: 01/2007